Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of etoposide, oxaliplatin and capecitabine in advanced hepatocellular carcinoma
2005-003187-32Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Dec 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide, oxaliplatin and capecitabine in hepatocellular carcinoma (HCC), sponsored by Rigshospitalet. Primary endpoint: Response rate. Started Dec 2005; status: completed.
02
Drugs
etoposideoxaliplatincapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2005-003187-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003187-32.